Search results for "Randomized Controlled Trial"

showing 10 items of 2199 documents

A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions

2018

Aims: The clinical value of percutaneous coronary intervention (PCI) for chronic coronary total occlusions (CTOs) is not established by randomized trials. This study should compare the benefit of PCI vs. optimal medical therapy (OMT) on the health status in patients with at least one CTO.Method and results: Three hundred and ninety-six patients were enrolled in a prospective randomized, multicentre, open-label, and controlled clinical trial to compare the treatment by PCI with OMT with a 2:1 randomization ratio. The primary endpoint was the change in health status assessed by the Seattle angina questionnaire (SAQ) between baseline and 12 months follow-up. Fifty-two percent of patients have …

Malemedicine.medical_specialtyRandomizationmedicine.medical_treatmentAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyAngina Pectorislaw.inventionAngina03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRandomized controlled triallawInternal medicinemedicineClinical endpointHumansPercutaneous transluminal interventioncardiovascular diseases030212 general & internal medicineMyocardial infarctionOptimal medical therapyAgedNitratesbusiness.industryAngina PectoriPercutaneous coronary interventionAngiotensin-Converting Enzyme InhibitorMiddle Agedmedicine.diseaseClinical trialCoronary OcclusionChronic coronary occlusion; EQ-5D; Optimal medical therapy; Percutaneous transluminal intervention; Seattle angina questionnaire; Cardiology and Cardiovascular MedicineConventional PCIChronic DiseaseChronic coronary occlusionQuality of LifeSeattle angina questionnaireFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitors
researchProduct

Lower Urinary Tract Symptoms: What's New in Medical Treatment?

2018

Abstract Context Pharmacological treatment is a cornerstone in the management of patients with lower urinary tract symptoms (LUTS). Objective To review emerging evidence in the medical treatment of LUTS. Evidence acquisition An Embase/Pubmed-based literature search was conducted in December 2017, screening for randomized controlled trials (RCTs), prospective and retrospective series, animal model studies, and reviews on medical treatment of LUTS. Evidence synthesis The main medical innovation in recent years in overactive bladder (OAB) has been the approval of the first β 3 -adrenoceptor agonists (mirabegron) and intradetrusor onabotulinum toxin A, while several other drugs such as antiepil…

Malemedicine.medical_specialtyReceptors VasopressinUrologyUrinary Bladder030232 urology & nephrologyUrologyProstatic HyperplasiaUrinary incontinenceAdrenergic beta-3 Receptor Agonistsurologic and male genital diseases03 medical and health sciences0302 clinical medicineLower Urinary Tract SymptomsLower urinary tract symptomsmedicineDesmopressin AcetateNocturiaHumansDeamino Arginine VasopressinProspective StudiesBotulinum Toxins Type ADesmopressinRandomized Controlled Trials as TopicRetrospective StudiesUrinary bladderbusiness.industryUrinary Bladder OveractiveAntidiuretic AgentsPhosphodiesterase 5 Inhibitorsmedicine.diseasefemale genital diseases and pregnancy complicationsThiazolesmedicine.anatomical_structureOveractive bladderClinical Trials Phase III as Topic030220 oncology & carcinogenesisModels AnimalAcetanilidesFemaleNocturiamedicine.symptomMirabegronbusinessmedicine.drugEuropean urology focus
researchProduct

Active compression-decompression resuscitation: a prospective, randomized study in a two-tiered EMS system with physicians in the field.

1996

Improved cardiopulmonary circulation with active compression-decompression cardiopulmonary resuscitation (ACD-CPR) has been demonstrated in studies using different animal models and a small number of humans in cardiac arrest (CA). However, prehospital studies have shown both positive and no extra benefit of ACD-CPR on return of spontaneous circulation (ROSC), hospital admission and discharge rates. The aim of our prospective study was to compare standard manual CPR (S-CPR) with ACD-CPR as the initial technique of resuscitating patients with out-of-hospital CA, with respect to survival rates and neurological outcome. Patients with out-of-hospital CA treated by emergency medical services (EMS…

Malemedicine.medical_specialtyResuscitationEmergency Medical ServicesDefibrillationmedicine.medical_treatmenteducationEmergency NursingReturn of spontaneous circulationlaw.inventionRandomized controlled triallawhealth services administrationmedicineEmergency medical servicesHumanscardiovascular diseasesCardiopulmonary resuscitationProspective StudiesProspective cohort studyhealth care economics and organizationsbusiness.industryIntensive care unitSurvival AnalysisCardiopulmonary ResuscitationSurgeryTreatment OutcomeAnesthesiaEmergency MedicineFemaleCardiology and Cardiovascular MedicinebusinesstherapeuticsResuscitation
researchProduct

Mucositis in irradiated cancer patients: effects of an antiseptic mouthrinse.

2009

Objective: To assess the effects of an antiseptic, non-alcohol based mouth-rinse containing chlorhexidine and cetylpyridinium chloride, in preventing the oral complications associated to radiation therapy in head-and-neck cancer patients. Study design: This was a parallel, double blind, prospective, randomized clinical trial. Cancer patients were randomly assigned to one of the two treatments (test mouth-rinse or a placebo). Three visits were scheduled (baseline, 14 and 28 days). Different outcome variables were evaluated: mucositis, plaque and gingival indices, stimulated saliva and salivary pH. Results: 70 patients were screened and 36 were included. The presence and the degree of mucosit…

Malemedicine.medical_specialtySalivamedicine.drug_classMouthwashesDentistryCetylpyridiniumPlaceboCetylpyridinium chloridelaw.inventionchemistry.chemical_compoundAntisepticRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineMucositisHumansProspective StudiesRadiation InjuriesGeneral DentistryStomatitisbusiness.industryChlorhexidineChlorhexidineCancerMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseOtorhinolaryngologychemistryHead and Neck NeoplasmsUNESCO::CIENCIAS MÉDICASAnti-Infective Agents LocalSurgeryFemalebusinessmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Water Infusion for Cecal Intubation Increases Patient Tolerance, but Does Not Improve Intubation of Unsedated Colonoscopies

2011

Background & Aims Several studies have indicated that water infusion, instead of air insufflation, enhances cecal intubation in selected patients undergoing unsedated colonoscopy. We performed a prospective, randomized, controlled trial to investigate whether the water technique increases the proportion of patients that are able to complete unsedated colonoscopy. Methods We analyzed data from 116 consecutive outpatients who were willing to start colonoscopy without sedation; 58 were each randomly assigned to groups given water infusion or air insufflation during the insertion phase. Sedation and analgesia were administered on demand. Results Fewer patients requested sedation in the water gr…

Malemedicine.medical_specialtySedationmedicine.medical_treatmentColonoscopylaw.inventionRandomized controlled triallawStatistical significancemedicineHumansHypnotics and SedativesIntubationProspective StudiesProspective cohort studyAgedWater infusionHepatologymedicine.diagnostic_testbusiness.industryAirGastroenterologyWaterInsufflationColonoscopyMiddle AgedSurgeryPatient toleranceAnesthesiaFemalemedicine.symptomIntubationbusinessClinical Gastroenterology and Hepatology
researchProduct

The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prosta…

2017

Two new drugs, the CYP17 inhibitor abiraterone acetate and the androgen receptor (AR) antagonist enzalutamide, have recently shown to prolong OS prior chemotherapy or in docetaxel treated mCRPC patients, using steroidal therapy or placebo as control group. Updated analyses underlined the role of these new agents on two prostate-specific endpoints as radiographic progression-free survival (rPFS) and time to first skeletal-related event (tSRE). On the basis of these reports, we made an indirect comparison between abiraterone and enzalutamide. We obtained a clinically but not significant difference favouring enzalutamide over abiraterone in terms of rPFS (HR 0.48, 95% CI 0.22–1.02). No signi…

Malemedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentUrologyAbiraterone AcetateBone NeoplasmsAbiraterone; Enzalutamide; mCRPC; rPFS; tSRE; Hematology; Oncology; Geriatrics and GerontologyPlaceboDisease-Free Survivallaw.invention03 medical and health scienceschemistry.chemical_compoundProstate cancer0302 clinical medicineRandomized controlled triallawNitrilesPhenylthiohydantoinEnzalutamideAndrogen Receptor AntagonistsMedicineEnzalutamideCytochrome P-450 Enzyme InhibitorsHumans030212 general & internal medicineProgression-free survivalAbirateronetSRERandomized Controlled Trials as TopicChemotherapybusiness.industryAbiraterone acetateHematologymCRPCmedicine.diseaseProstatic Neoplasms Castration-ResistantTreatment OutcomechemistryDocetaxelrPFSOncology030220 oncology & carcinogenesisBenzamidesDisease ProgressionGeriatrics and Gerontologybusinessmedicine.drugCritical reviews in oncology/hematology
researchProduct

Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in pati…

2010

Background: Epidemiologic studies indicate that elevated heart rate (HR) is an independent risk factor for mortality and morbidity in patients (pts) with chronic heart failure (CHF). Clinical trials with b-blockers suggest that HR reduction is an important mechanism of their benefit in pts with stable CHF. Pharmacologic inhibition of the If current now provides the opportunity of pure HR reduction. The purpose of this study was to evaluate the impact of ‘‘Off-Label’’ use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in pts with ischemic CHF. Methods: Between January 2008 and June 2008, a graded maximal exercise test with re…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaAdrenergic beta-AntagonistsOff-label uselaw.inventionOxygen ConsumptionQuality of lifeRandomized controlled triallawHeart RateInternal medicinemedicineHumansPharmacology (medical)IvabradineExercise physiologyRisk factorExercisePharmacologyHeart Failureivabradine heart failure exercise capacityNeurotransmitter AgentsExercise Tolerancebusiness.industryOff-Label UseBenzazepinesmedicine.diseaseClinical trialHeart failureChronic DiseaseCardiologyExercise TestQuality of LifeFemaleCardiology and Cardiovascular MedicinebusinessIvabradinemedicine.drugJournal of cardiovascular pharmacology and therapeutics
researchProduct

Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercho…

2013

Hypercholesterolemic patients (n = 1,547) at high atherosclerotic cardiovascular disease risk with low-density lipoprotein cholesterol (LDL-C) levels ≥100 and ≤160 mg/dl while treated with atorvastatin 10 mg/day entered a multicenter, randomized, double-blind, active-controlled, clinical trial using two 6-week study periods. Period I compared the efficacy/safety of (1) adding ezetimibe 10 mg (ezetimibe) to stable atorvastatin 10 mg, (2) doubling atorvastatin to 20 mg, or (3) switching to rosuvastatin 10 mg. Subjects in the latter 2 groups who persisted with elevated LDL-C levels (≥100 and ≤160 mg/dl) after period I, entered period II; subjects on atorvastatin 20 mg had ezetimibe added to th…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaAtorvastatinHypercholesterolemiaUrologylaw.inventionchemistry.chemical_compoundEzetimibeRandomized controlled trialDouble-Blind Methodlawhealth services administrationInternal medicineprimary hypercholesterolemiaatorvastatin; ezetimibe; rosuvastatin; primary hypercholesterolemiamedicineAtorvastatinHumansRosuvastatinIn patientPyrrolescardiovascular diseasesRosuvastatin CalciumAgedSulfonamidesCholesterolbusiness.industryAnticholesteremic Agentsnutritional and metabolic diseasesCholesterol LDLMiddle AgedEzetimibeClinical trialFluorobenzenesRosuvastatin CalciumLogistic ModelsPyrimidineschemistryHeptanoic AcidsCardiologyAzetidineslipids (amino acids peptides and proteins)Drug Therapy CombinationFemaleCardiology and Cardiovascular Medicinebusinessrosuvastatinmedicine.drugThe American journal of cardiology
researchProduct

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

2015

BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy.METHODS: We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy. Patients were …

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaIntention to Treat AnalysiHypercholesterolemiaUrologyalirocumabBococizumabPharmacologyPlaceboAged; Antibodies Monoclonal; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Drug Therapy Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intention to Treat Analysis; Male; Middle Aged; Medicine (all)law.inventionchemistry.chemical_compoundcardiovascular eventsDouble-Blind MethodRandomized controlled triallawCardiovascular DiseaseAnticholesteremic AgentMedicineproprotein convertase subtilisin–kexin type 9 (PCSK9)High Cardiovascular Risk PatientsAgedAlirocumabalirocumab; cholesterol; cardiovascular eventsCholesterolbusiness.industryMedicine (all)PCSK9Antibodies MonoclonalcholesterolCholesterol LDLGeneral MedicineMiddle AgedLomitapideEvolocumabchemistrylow-density lipoprotein (LDL) cholesterol[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorbusiness[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHumanNew England journal of medicine
researchProduct

Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicentre Italian CORIST Study

2021

Abstract Introduction A hypercoagulable condition was described in patients with coronavirus disease 2019 (COVID-19) and proposed as a possible pathogenic mechanism contributing to disease progression and lethality. Aim We evaluated if in-hospital administration of heparin improved survival in a large cohort of Italian COVID-19 patients. Methods In a retrospective observational study, 2,574 unselected patients hospitalized in 30 clinical centers in Italy from February 19, 2020 to June 5, 2020 with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 infection were analyzed. The primary endpoint in a time-to event analysis was in-hospital death, comparing patients who receive…

Malemedicine.medical_specialtySettore MED/17 - Malattie Infettivecoronavirusheparin030204 cardiovascular system & hematologyLower risklaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineClinical endpointmedicineHumansThrombophilia030212 general & internal medicineHospital MortalityBlood CoagulationSurvival analysisAgedRetrospective Studiestreatmentbusiness.industryHeparinMortality rateCOVID-19mortalityLow-Molecular-WeightAnticoagulantsCOVID-19Retrospective cohort studyHeparinHematologyHeparin Low-Molecular-WeightMiddle AgedmortalitySurvival AnalysisCOVID-19 Drug Treatmentcoagulation activationcoronaviruItalytreatmentsPropensity score matchingcoagulation activation; coronavirus; COVID-19; heparin; mortality; treatmentsFemalecoagulation activation; coronavirus; COVID-19; heparin; mortality; treatments; Aged; Anticoagulants; Blood Coagulation; COVID-19; Female; Heparin; Heparin Low-Molecular-Weight; Hospital Mortality; Humans; Italy; Male; Middle Aged; Retrospective Studies; Survival Analysis; Thrombophiliabusinessmedicine.drug
researchProduct